Cohort study on the treatment of BRAF V600E mutant metastatic colorectal cancer with integrated Chinese and western medicine

Table 1 Baseline characteristics of patients, n (%)

Project	Cohort A (n = 23)	Cohort B (n = 11)	Rank sum /χ2 /Fisher’s test	P value
Age (year)	54 (51.64)	53 (44.70)	-0.387	0.698
Gender
Male	12 (52.17)	4 (36.36)	-	0.477
Female	11 (47.83)	7 (63.63)
Primary site
Right-side colon	12 (52.17)	6 (54.55)	0.017	0.896
Left-side colon	11 (47.83)	5 (45.45)
Liver metastasis
Yes	11 (47.83)	5 (45.45)	0.017	0.896
No	12 (52.17)	6 (54.55)
Peritoneal metastasis
Yes	5 (21.74)	3 (27.27)	-	1.000
No	18 (78.26)	8 (72.73)
Chemotherapy
Yes	16 (69.57)	11 (100.00)	-	0.069
No	7 (30.43)	0 (0.00)
Targeted therapy
Yes	14 (60.87)	6 (54.55)	0.122	0.726
No	9 (39.13)	5 (45.45)

Table 2 Subgroup analysis

Subgroup	mOS (month)		χ2	P value	HR (95%CI)
	Cohort A	Cohort B
Right-side colon	25.5	10.15	6.335	0.012	0.25 (0.07, 0.83)
Liver metastasis	21	8.1	7.192	0.007	0.22 (0.06, 1.80)
Targeted therapy	26	13.2	3.918	0.073	0.40 (0.14, 1.20)
Chemotherapy	21	14.2	5.475	0.019	0.38 (0.17, 0.90)
First-line treatment	21	13.2	8.597	0.003	0.25 (0.09, 0.67)

mOS: Median overall survival.